Know Cancer

forgot password

Phase II Trial of TACE With Sorafenib in Patients With Locally Advanced Hepatocellular Carcinoma

Phase 2
18 Years
Open (Enrolling)
Hepatocellular Carcinoma

Thank you

Trial Information

Phase II Trial of TACE With Sorafenib in Patients With Locally Advanced Hepatocellular Carcinoma

Inclusion Criteria:

1. Unresectable Hepatocellular carcinoma with local liver lesion treatable with TACE

2. Age > 18 years.

3. ECOG Performance Status of 0 or 1.

4. Child-Pugh class A (class B could be included when Childs score is 7).

5. Life expectancy of at least 12 weeks.

6. Subjects with at least one measurable lesion.

7. Adequate bone marrow, liver and renal function as assessed by the following
laboratory requirements to be conducted within 7 days prior to screening:

- Hemoglobin > 9.0 g/dl

- Absolute neutrophil count (ANC) >1,500/mm3

- Platelet count > 75,000/μl

- Total bilirubin < 1.5 times the upper limit of normal

- ALT and AST < 2.5 x upper limit of normal (UNL)

- Alkaline phosphatase < 5 x ULN

- PT-INR/PTT < 1.5 x upper limit of normal

- Serum creatinine < 1.5 x ULN

8. Signed and dated informed consent before the start of specific protocol procedures

Exclusion Criteria:

1. History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI
more than 6 mo prior to study entry is allowed); cardiac arrythmias requiring
anti-arrythmic therapy( beta blockers or digoxin are permitted) or uncontrolled

2. History of HIV infection.

3. Active clinically serious infections (> grade 2 NCI-CTC version 3.0)

4. Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months
from definitive therapy, has a negative imaging study within 4 weeks of study entry
and is clinically stable with respect to the tumor at the time of study entry)

5. Patients with seizure disorder requiring medication (such as steroids or

6. History of organ allograft The organ allograft may be allowed as protocol specific.

7. Patients with evidence or history of uncontrolled bleeding diathesis

8. Patients undergoing renal dialysis

9. Previous or concurrent cancer that is distinct in primary site or histology from the
cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal
cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively
treated > 3 years prior to study entry.

10. Excluded therapies and medications, previous and concomitant:

- Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of
study entry

- Radiotherapy during study or within 3 weeks of start of study drug. (Palliative
radiotherapy will be allowed). Major surgery within 4 weeks of start of study

- Investigational drug therapy outside of this trial during or within 4 weeks of
study entry

- Prior exposure to the study drug.

- Pregnant or breast-feeding patients. Women of childbearing potential must have a
negative pregnancy test performed within 7 days of the start of treatment. Both
men and women enrolled in this trial must use adequate barrier birth control
measures during the course of the trial (and men for at least 3 months after
last administration of study medication).

- Substance abuse, medical, psychological or social conditions that may interfere
with the patient's participation in the study or evaluation of the study results

- Any condition that is unstable or could jeopardize the safety of the patient and
their compliance in the study

- Patients unable to swallow oral medications

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Time to progression

Outcome Description:

Assessments including image and laboratory studies will take place within 7days of the every TACE cycle

Outcome Time Frame:

2 year

Safety Issue:


Principal Investigator

Joung-Soon Jang, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Chung-Ang University Hospital


Korea: Institutional Review Board

Study ID:

CAUHHO 2009-1



Start Date:

June 2009

Completion Date:

June 2013

Related Keywords:

  • Hepatocellular Carcinoma
  • Hepatocellular Carcinoma
  • Sorafenib
  • TACE
  • locally, advanced Hepatocellular Carcinoma
  • Carcinoma
  • Carcinoma, Hepatocellular